Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company earned $10 million during the quarter, compared to analyst estimates of $9.33 million. During the same period in the prior year, the business posted ($0.30) EPS. View Conatus Pharmaceuticals' Earnings History.

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Conatus Pharmaceuticals.

7 analysts have issued twelve-month price objectives for Conatus Pharmaceuticals' shares. Their forecasts range from $7.00 to $26.00. On average, they anticipate Conatus Pharmaceuticals' share price to reach $14.67 in the next twelve months. View Analyst Ratings for Conatus Pharmaceuticals.

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Conatus presently has no approved product in its portfolio. However, its progress with the lead candidate, emricasan has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Moreover, the stock has outperformed the industry in the last one year. On the flip side, though emricasan is progressing well, it is still several years away from entering the market, if at all. Any development/regulatory setback could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/24/2017)
• 2. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
• 3. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)

Some companies that are related to Conatus Pharmaceuticals include CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals Holdings (CRBP), Merus N.V. (MRUS), BioTime (BTX), Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Minerva Neurosciences (NERV), Athersys (ATHX), Madrigal Pharmaceuticals (MDGL), Stemline Therapeutics (STML), Oxford BioMedica plc (OXB), Immune Design Corp. (IMDZ), Arrowhead Pharmaceuticals (ARWR), Forward Pharma A/S (FWP), Ardelyx (ARDX), DURECT Corporation (DRRX), uniQure N.V. (QURE) and Circassia Pharmaceuticals PLC (CIR).

Conatus Pharmaceuticals' management team includes the folowing people:

• David F. Hale, Independent Chairman of the Board
• Steven J. Mento Ph.D., President, Chief Executive Officer, Director
• Keith W. Marshall, Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President
• Alfred P. Spada Ph.D., Executive Vice President - Research & Development, Chief Scientific Officer
• David T. Hagerty M.D., Executive Vice President, Clinical Development
• Daniel L. Ripley, Senior Vice President - Business Development, Program and Alliance Management
• Edward F. Smith III., Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
• Michelle L Vandertie, Acting Principal Accounting Officer
• Daniel L. Kisner M.D., Additional Independent Director
• Preston S. Klassen M.D., Additional Independent Director

Conatus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include MPM Asset Management LLC (4.24%), Acadian Asset Management LLC (4.20%), Vanguard Group Inc. (3.58%), AXA (1.60%), State Street Corp (1.21%) and Northern Trust Corp (1.06%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Conatus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AXA. View Insider Buying and Selling for Conatus Pharmaceuticals.

Conatus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, State Street Corp, Numeric Investors LLC, Northern Trust Corp, Vanguard Group Inc., Schwab Charles Investment Management Inc., Russell Investments Group Ltd. and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Conatus Pharmaceuticals.

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $5.38.